Use of a poly(adp-ribose) polymerase (parp) inhibitor in the manufacture of a medicament for treatment of cancer which is deficient in the hr dependent dna dsb repair pathway

摘要

The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.